Balaji Amines conducted their Conference Call today at 4:00 pm.
Here are the key takeaways π
Business Updates:
β’ EBIDTA growth- 78% Driver were increasing demand and improving price realization.
β’ Zero debt co. on standalone basis.
β’ Certain product are now exported to China.
Ethylamines:
β’ With implementation of new technology the cost of production is expected to lower.
β’ Demand is India is expected to increase by 12-15% over years.
β’ Import of Ethylamines is 9,000 Tones in India.
β’ Majority will be sell directly in market.
Acetonitrile:
β’ De-bottlenecking is delayed on account of lack of skilled manpower due to pandemic led restrictions.
β’ RM price of Acetonitrile has gone up.
DMC:
β’ DMC in Phase I, is undergoing and is expected to commence by the end of FY22
DMF Production:
β’ During pandemic due to oxygen diversification in healthcare, production was slowed down. Now it is back to normal.
β’ DMF Prices has been around 150-160Rs
β’ Total 30K capacity is there.
Covid Vaccine:
β’ In the all the 3 vaccine, Covaxin, Sputnik and Covi-shield, there is small content of TDTA, Acetic Acid, which goes for manufacturing of covid. But it is very small quantity.
CAPEX:
β’ Phase 1 spend was - 151 cr
β’ Methyl Amines is expected to commission from the end of year.
β’ Capex Plans in image.
Export:
β’ There were logistics issue going on, but still Balaji has done 185 crore of export.
β’ As logistics issue got resolved, there are much of growth available.
Raw Material:
β’ Prices has been little cooled off, and now the prices can be easily passed on to the customer.
β’ Logistics issue is going on, but co. is planning for advance order, hence there wont be issue in most of product.
Subsidiary:
β’ Subsidiaries are expected grow well in the coming 2-3 quarter.
β’ Margins are expected to improve, if Balaji could avail the RM at good price.
For more discussion on Equity research and OI analysis
IG Petrochemicals Ltd. Conducted their conference call today at 3:30 pm.
" To become a well diversified chemical company with leadership in PAN* Industry. "
Here are the key takeaways π...
Business Overview
- Company has given robust growth in both QoQ and YoY basis.
- They still maintain their position of being the largest manufacturer of phthalic Anhydride (PAN) and maleic anhydride.(MAN)
- With government demand being bullish on downstream products like Paints, Plasticizers, UPR and all , there will be demand of PAN in domestic markets.
- They have a positive correlation with the infrastructure industry leading to a strong demand growth.
Godawari Power & Ispat conducted their conference call today at 12 noon
"Co. is targeting to be debt free company soon"
Here are the key takeaways π
Business Updates:
β’ In- plant power generation capacity of 73 MW
β’ Thermal Power is yielding 12%, hence co. is expanding in Solar Pvr
β’ Utilization level- 92-95%
β’ Iron Ore availability is expected to consistent from this year
β’ MOU signed with Chattigarh for future project
Solar PV Power:
β’ Setting up a 250 MW captive Solar PV power plant to replace existing thermal capacity.
β’ Project will commissioned in Q3 Fy 2023.
β’ Project Dynamics of project mentioned in image
β’ Expected returns is 24%, hence now Godawari is investing heavily.
Indoco Remedies Ltd. Conducted their conference call today at 3:30 pm.
" Company motivated to earn 19% above CAGR"
Here are the key takeaways π
Business Overview
- Company have nominal profit on YoY basis and has experienced a decline in growth on QoQ basis.
- Company still remains bullish on their key segments for further growth.
- The major impacted acute segment witness strong hit due to fall in demand.
- The Company experience about 20% de growth in the prescription buisness. And as the covid situation is falling apart they will be able to cover up the losses.
- Their Domestic business has taken the major hit this quarter but was covered somewhat by international growth.
Alkem Laboratories conducted their conference call today at 4:30.
"Guidance for EBIDTA margins to be around 20%"
Here are the key takeaways π
Business Update:
β’ India business grew 17.1% YoY.
β’ Therapy segment grew well, of which major contribution of growth is Anti-Diabetic, Neuro, Vitamins, Gastro.
β’ In this quarter Alkem has filed 4 new ANDA and received 10 approvals.
FY21- 9 ANDA filed with 25 approval.
Gross Margin:
β’ Inventory Provision of 80 cr was taken, which declined margins.
β’ In More than 6 months inventory, if NRV seems to be unrecognizable, provision is made.